Get the Daily Brief
Latest Biotech News
Theravance slashes R&D — halts pipeline after late‑stage failure
Theravance Biopharma announced a sweeping restructuring after its norepinephrine reuptake inhibitor ampreloxetine failed a Phase III study in multiple system atrophy and symptomatic neurogenic...
Prime to test FDA flexibility — seeks approval on a two‑patient gene edit
Prime Medicine reversed an earlier decision to shelve PM359 and said it will pursue FDA approval for the prime‑editing therapy for chronic granulomatous disease (CGD) using data from just two...
Liquid biopsy moves beyond cancer — cfDNA fragmentomics IDs liver disease
Researchers from Johns Hopkins, Delfi Diagnostics and collaborators demonstrated that cfDNA fragmentomics can detect liver diseases such as cirrhosis and fibrosis from plasma samples, extending...
AGBT signals a high‑throughput shakeup — sequencing and spatial updates
The Advances in Genome Biology and Technology meeting revealed incremental but important advances across sequencing and spatial biology that together could reshape clinical and discovery...
ARPA‑H awards $21.8M — funds Georgia Tech lymphatic disease therapeutic effort
The Advanced Research Projects Agency for Health (ARPA‑H) awarded up to $21.8 million to Georgia Tech to develop a first‑of‑its‑kind therapeutic intervention for lymphatic diseases. The program...
Stanford debuts iISM — label‑free microscope shows live cells at 120‑nm resolution
Stanford researchers introduced interferometric Image Scanning Microscopy (iISM), a label‑free imaging technique that combines interferometry and image‑scanning methods to visualize live cellular...
Roche commits $480M to South Korea — builds a global clinical‑trial ecosystem
Roche announced a $480 million commitment to expand South Korea’s biopharma infrastructure and attract global clinical trials, aiming to position the country as a major trial hub. The investment...
Evo 2 DNA model: AI designs genomes across the tree of life
A DNA foundation model called Evo 2 was published in Nature and can identify patterns across the genomes of more than 100,000 species and design long genomic sequences. The model accurately flags...
Prime Medicine reverses course – pursues FDA approval for prime‑editing therapy
Prime Medicine has reversed an earlier decision to shelve a gene‑editing program and will seek FDA approval for a prime‑editing therapy after treating only two patients, according to company...
Moderna pays big: upfront cash in global LNP patent settlement
Moderna agreed to settle long‑running patent litigation over lipid nanoparticle (LNP) delivery technology with Roivant’s Genevant and Arbutus, paying $950 million upfront and up to $2.25 billion...
FDA targets compounders: fresh warning letters hit GLP‑1 telehealth sellers
The U.S. Food and Drug Administration sent a new batch of warning letters—30 in the latest round—targeting telehealth companies that marketed compounded versions of GLP‑1 obesity drugs and made...
Theravance winds down R&D after phase III failure – major layoffs follow
Theravance Biopharma announced the end of its R&D organization and a 50% workforce reduction after its phase III trial of ampreloxetine failed to meet the primary endpoint. The company will pivot...
AGBT reveals high‑throughput sequencing arms race: Illumina faces new rivals
At the Advances in Genome Biology and Technology meeting, multiple companies unveiled high‑throughput sequencing updates that collectively threaten Illumina’s clinical pricing and capacity...
Cellanome R3200: live‑cell imaging tied to sequencing for longitudinal functional analysis
Cellanome commercialized the R3200 platform that integrates live‑cell imaging, AI segmentation, micro‑3D printing and sequencing to link phenotypes to transcriptomes in longitudinal experiments,...
GSK licenses Frontier’s siRNA assets: $40M upfront, near‑$1B upside
GlaxoSmithKline signed a global exclusive license with China’s Frontier Biotechnologies for two siRNA candidates in immunology, paying $40 million up front and up to $963 million in milestones....
UCB enters T‑cell engager race: $80M upfront for Antengene’s CD19xCD3 asset
UCB licensed ATG‑201, a CD19xCD3 T‑cell engager developed by Shanghai‑based Antengene, paying $80 million up front with up to $1.1 billion in milestones and tiered royalties. Antengene will...
Atrium Therapeutics spins out to focus on RNA therapies for cardiomyopathies
Atrium Therapeutics launched as a public company following Novartis’ acquisition of Avidity, carrying roughly $270 million in cash and two lead RNA‑delivery candidates targeting PRKAG2 syndrome...
Moderna to pay $950M upfront — settles long-running Covid vaccine patent fight
Moderna agreed to a near‑term settlement that will resolve long‑running patent litigation tied to its Covid‑19 vaccine. The company will pay $950 million upfront to Arbutus Biopharma and Roivant’s...
Theravance winds down R&D — halves workforce after Phase III failure
Theravance Biopharma announced an immediate strategic retrenchment after its lead candidate failed a pivotal Phase III study, prompting the company to terminate R&D activities and cut its...
UCB inks Antengene TCE pact: Belgian drugmaker steps into bispecific space
UCB struck licensing agreements with Shanghai‑based Antengene to enter the crowded T‑cell engager (TCE) arena, acquiring rights to Antengene’s CD19xCD3 candidate with a mix of upfront payments and...